The numbers, to scale
Sum of every GLP-1 brand's total spending. Source: CMS Medicare Part D Spending by Drug, updated June 25, 2026.
Each brand's total Part D spending, all manufacturers combined.
Every GLP-1 brand in Part D (11), highest 2024 spending first
| Brand | Generic | 2020 | 2024 spending | Claims | Beneficiaries | Per beneficiary |
|---|---|---|---|---|---|---|
| Ozempic | Semaglutide | $1,455,812,267 | $12,970,296,347 | 10,417,182 | 1,952,637 | $6,642 |
| Mounjaro | Tirzepatide | None reported | $6,336,942,641 | 5,105,397 | 894,581 | $7,084 |
| Trulicity | Dulaglutide | $3,284,873,062 | $5,454,134,725 | 4,305,141 | 788,716 | $6,915 |
| Rybelsus | Semaglutide | $73,444,409 | $1,890,082,026 | 1,251,733 | 309,993 | $6,097 |
| Wegovy | Semaglutide | None reported | $301,283,291 | 211,575 | 52,961 | $5,689 |
| Bydureon Bcise | Exenatide Microspheres | $266,160,951 | $215,354,678 | 178,931 | 38,059 | $5,658 |
| Victoza 3-Pak | Liraglutide | $1,545,815,415 | $203,063,050 | 181,068 | 62,754 | $3,236 |
| Victoza 2-Pak | Liraglutide | $349,476,159 | $77,832,721 | 108,521 | 41,126 | $1,893 |
| Liraglutide | Liraglutide | None reported | $48,095,824 | 62,254 | 24,405 | $1,971 |
| Byetta | Exenatide | $47,676,632 | $15,877,480 | 11,712 | 3,043 | $5,218 |
| Zepbound | Tirzepatide | None reported | $387,343 | 353 | 245 | $1,581 |
"None reported" marks years a brand had no Part D spending reported (it was not yet approved or not covered). The export carries every year. All 11 rows, with every column, are in the CSV and JSON.
How the number is computed
Sum of "Total Spending" for each year across every GLP-1 brand's "Overall" row (all manufacturers combined) in CMS's Medicare Part D Spending by Drug dataset, data year 2024.
Included
- Brands: Ozempic, Mounjaro, Trulicity, Rybelsus, Wegovy, Bydureon Bcise, Victoza 3-Pak, Victoza 2-Pak, Liraglutide, Byetta, Zepbound.
Excluded
- Insulin combinations: Soliqua (insulin glargine and lixisenatide); Xultophy (insulin degludec and liraglutide).
- Beneficiaries are not summed across brands: one person can fill two brands in a year.
Read it with care
- Spending is gross drug cost (what plans and patients paid pharmacies), before manufacturer rebates and discounts.
- Medicare Part D does not cover drugs prescribed for weight loss alone; most of this spending is for type 2 diabetes, with Wegovy and Zepbound covered for other approved uses.
- CMS flags a brand-year as an outlier when its average spending per unit looks unusual: Wegovy 2023.
Receipts
2 sources · read October 4, 2026
- 01read
Five calendar years per brand: total spending, claims, dosage units, beneficiaries.
CMS, Medicare Part D Spending by Drug, data year 2024 (data.cms.gov), updated June 25, 2026 - 02read
Cite this
Free to reuse under CC BY 4.0: quote the number, credit PriceTracker GLP-1 with a link, and name the federal source. The underlying records are public; our counts, matching and files are the work you are crediting.
PriceTracker GLP-1. (2026, October 4). Medicare Part D spending on GLP-1 drugs, 2020 to 2024 [Data set]. Based on Centers for Medicare & Medicaid Services data, cms data updated June 25, 2026. https://pricetrackerglp1.com/data/medicare-part-d-glp1-spending
<p>Medicare Part D spent $27.5 billion on GLP-1 drugs in 2024, up from $7.0 billion in 2020, according to CMS Medicare Part D Spending by Drug data updated June 25, 2026. Source: <a href="https://pricetrackerglp1.com/data/medicare-part-d-glp1-spending">PriceTracker GLP-1</a> (CC BY 4.0).</p>
https://pricetrackerglp1.com/data/medicare-part-d-glp1-spending.csv https://pricetrackerglp1.com/data/medicare-part-d-glp1-spending.json